etiolog
agent
sever
acut
respiratori
syndrom
sar
identifi
novel
coronaviru
sarscov
similar
coronavirus
spike
glycoprotein
viru
interact
cellular
receptor
mediat
membran
fusion
allow
viral
entri
suscept
target
cell
accordingli
sprotein
play
import
role
viru
infect
cycl
primari
target
neutral
antibodi
begin
understand
biochem
immunolog
properti
express
fulllength
ectodomain
protein
variou
primat
cell
result
show
protein
electrophoret
mobil
kda
protein
glycosyl
high
mannos
andor
hybrid
oligosaccharid
account
approxim
kda
appar
protein
mass
detect
sprotein
immunoassay
difficult
use
human
convalesc
sera
suggest
protein
may
elicit
strong
humor
immun
respons
virusinfect
patient
abl
pseudotyp
murin
leukemia
viru
particl
sprotein
produc
sar
pseudovirus
pseudovirus
infect
vero
cell
phindepend
manner
infect
could
specif
inhibit
convalesc
sera
consist
low
level
antibodi
sprotein
neutral
activ
weak
neutral
titer
rang
facilit
quantifi
pseudovirusinfect
cell
stain
blue
xgal
devis
autom
procedur
use
elispot
analyz
highthroughput
capac
procedur
safeti
use
sar
pseudovirus
make
possibl
largescal
analys
neutral
antibodi
respons
sarscov
first
epidem
sever
acut
respiratori
syndrom
sar
began
novemb
guandong
provinc
peopl
republ
china
last
month
close
peopl
infect
worldwid
among
peopl
die
etiolog
agent
atyp
respiratori
diseas
identifi
novel
coronaviru
design
sarscov
fouchier
et
al
ksiazek
et
al
peiri
et
al
poutanen
et
al
mortal
rate
sarscov
major
health
socioeconom
impact
fortun
incid
sar
infect
winter
season
howev
multipl
mode
viru
transmiss
wide
rang
potenti
nonhuman
reservoir
includ
wild
anim
commonli
found
market
eg
civet
cat
raccoon
dog
guan
et
al
well
domest
cat
martina
et
al
highli
like
viru
natur
certainli
resurfac
futur
current
antivir
drug
immunotherapeut
agent
vaccin
avail
viru
better
control
prevent
futur
epidem
antisarscov
drug
andor
vaccin
need
develop
sarscov
belong
coronavirida
famili
genom
organ
viru
similar
coronavirus
gener
order
replicas
rep
spike
glycoprotein
envelop
e
membran
protein
nucleocapsid
n
direct
marra
et
al
rota
et
al
fig
sever
openread
frame
also
identifi
may
encod
addit
protein
marra
et
al
rota
et
al
snijder
et
al
function
howev
known
present
time
protein
major
interest
target
antivir
drug
develop
effort
well
develop
vaccin
sglycoprotein
sprotein
coronavirus
thought
function
trimer
delma
laud
respons
bind
cellular
receptor
induc
membran
fusion
viru
entri
target
cell
collin
et
al
godet
et
al
kubo
et
al
mutat
protein
shown
alter
virul
cellular
tropism
fazakerley
et
al
leparcgoffart
et
al
sanchez
et
al
taken
togeth
sprotein
play
critic
role
biolog
pathogenesi
coronavirus
surprisingli
import
target
virusneutr
antibodi
chang
et
al
collin
et
al
fleme
et
al
godet
et
al
kant
et
al
kubo
et
al
kubo
et
al
takaseyoden
et
al
moreov
mice
immun
recombin
sprotein
peptid
deriv
protect
lethal
challeng
murin
hepat
viru
mhv
daniel
talbot
koo
et
al
sprotein
type
membran
glycoprotein
translat
membranebound
polysom
insert
rough
endoplasm
reticulum
rer
cotransl
glycosyl
transport
golgi
complex
transport
sprotein
incorpor
onto
matur
viru
particl
assembl
bud
compart
lie
rer
golgi
lai
holm
virion
carri
golgi
plasma
membran
secretori
vesicl
virion
releas
cell
virioncontain
vesicl
fuse
plasma
membran
excess
sprotein
incorpor
onto
viru
particl
transport
surfac
plasma
membran
lai
holm
tsai
et
al
yamada
et
al
sprotein
sarscov
amino
acid
long
fig
predict
amino
acid
signal
peptid
aminoterminu
singl
ectodomain
amino
acid
transmembran
region
follow
short
cytoplasm
tail
residu
carboxyterminu
marra
et
al
rota
et
al
due
low
sequenc
homolog
sprotein
sarscov
coronavirus
marra
et
al
rota
et
al
structur
immunogen
properti
sarscov
sprotein
must
ascertain
experiment
cellular
receptor
sarscov
recent
identifi
angiotensinconvert
enzym
li
et
al
molecular
interact
sprotein
yet
known
better
understand
interact
could
lead
develop
viru
entri
inhibitor
neutral
antibodi
nab
play
critic
role
protect
varieti
viral
diseas
accur
assess
nab
respons
virusinfect
patient
need
determin
immun
correl
protect
also
essenti
integr
part
vaccin
develop
process
convent
virusneutr
assay
requir
use
replicationcompet
infecti
virus
evalu
virusneutr
activ
larg
number
antisera
assay
undesir
due
safeti
concern
especi
biosafeti
level
pathogen
like
sarscov
safeti
concern
prompt
laboratori
util
replicationdefect
pseudovirus
neutral
assay
kim
et
al
assay
nonrepl
moloney
murin
leukemia
viru
mulv
particl
pseudotyp
envelop
glycoprotein
use
schnierl
et
al
pseudovirus
encod
hgalactosidas
gene
allow
detect
individu
infect
cell
stain
xgal
studi
report
develop
sarscov
pseudoviru
neutral
assay
particularli
valuabl
research
may
easi
access
contain
facil
addit
describ
highthroughput
system
quantit
analys
xgal
stain
cell
assay
system
facilit
rapid
evalu
antibodi
respons
vaccin
candid
andor
entri
inhibitor
sarscov
express
sarscov
sglycoprotein
initi
clone
dna
fragment
encod
protein
vector
pcdna
fig
detect
sprotein
western
blot
perform
convalesc
sera
sarscovinfect
patient
howev
clear
protein
band
detect
despit
number
attempt
reason
one
possibl
inabl
detect
protein
low
level
sprotein
express
pcdna
increas
amount
sprotein
express
subclon
gene
phcmvg
vector
burn
et
al
express
high
level
vesicular
stomat
viru
vsv
g
glycoprotein
although
abl
express
higher
amount
sprotein
see
suffici
detect
clear
band
western
blot
altern
explan
antibodi
protein
convalesc
sera
recogn
sprotein
subject
denatur
condit
sdspage
viz
linear
epitop
howev
result
radioimmunoprecipit
indirect
immunofluoresc
assay
also
ambigu
like
antibodi
titer
sprotein
low
convalesc
sera
increas
protein
express
level
gene
subclon
ptm
vector
moss
et
al
vector
protein
interest
control
strong
rna
polymeras
promot
protein
express
cell
transfect
plasmid
infect
recombin
vaccinia
viru
express
fuerst
et
al
presenc
encephalomyocard
viru
intern
ribosom
entri
site
ire
end
rna
transcript
allow
effici
translat
mrna
transcrib
cytoplasm
use
ptm
abl
detect
faint
distinct
band
approxim
kda
western
blot
fig
lane
also
reevalu
pcdna
vector
dual
promot
system
cmv
promot
use
promot
abl
detect
protein
band
similar
size
albeit
less
clear
use
ptm
lane
lower
express
protein
like
due
lack
ire
pcdna
vector
calcul
molecular
weight
sprotein
without
amino
acid
signal
peptid
kda
result
suggest
posttransl
modif
eg
glycosyl
better
demonstr
gener
anoth
clone
ptmeshi
express
entir
ectodomain
sprotein
amino
acid
sixhistidin
tag
carboxi
terminu
ectodomain
sprotein
migrat
approxim
molecular
weight
kda
calcul
molecular
weight
kda
fig
lane
demonstr
differ
due
glycosyl
eshi
protein
treat
endoglycosidas
h
endoh
peptid
nglycosidas
f
pngase
f
shown
fig
lane
treatment
either
glycosidas
increas
mobil
protein
approxim
kda
mobil
protein
treat
either
glycosidas
sprotein
like
modifi
high
mannos
andor
hybrid
rather
complex
oligosaccharid
sglycoprotein
coronavirus
cleav
two
subdomain
fact
observ
singl
band
suggest
sarscov
sprotein
function
singl
unit
despit
difficulti
detect
sprotein
directli
immunoassay
protein
express
pcdna
phcmv
construct
abl
pseudotyp
mulv
particl
produc
sar
pseudovirus
could
readili
infect
vero
cell
fig
none
cell
line
test
includ
hela
suscept
contrast
vsvg
pseudotyp
virus
could
infect
cell
line
data
shown
fact
cell
like
vero
cell
african
green
monkey
kidney
cell
suscept
somewhat
unexpect
howev
perform
infect
high
multipl
infect
abl
detect
infect
albeit
significantli
reduc
titer
compar
vero
cell
data
shown
result
surpris
shown
even
cell
express
small
amount
support
basal
level
sarscov
replic
mani
pseudovirusinfect
cell
appear
doublet
result
cell
divis
follow
integr
mulv
pseudoviru
genom
encod
hgalactosidas
doublet
count
singl
infecti
unit
typic
yield
sar
pseudovirus
infecti
unit
per
millilit
cultur
supernat
use
phcmv
fivefold
greater
use
yield
compar
abl
achiev
pseudovirus
depend
envelop
kim
et
al
lower
vsvg
pseudoviru
yield
depend
target
cell
line
use
interestingli
sar
pseudoviru
product
less
effici
plasmid
transfect
perform
calcium
phosphat
method
compar
use
cation
lipid
lipofect
differ
howev
observ
vsvg
pseudoviru
product
addit
differ
longer
incub
time
need
achiev
peak
pseudoviru
product
sarss
compar
vsvg
vs
day
posttransfect
respect
reason
discord
result
unknown
present
time
cellular
entri
coronavirus
occur
either
acid
phdepend
independ
pathway
gallagh
et
al
lai
holm
cavanagh
nash
buchmeier
payn
et
al
investig
whether
sarscov
infect
requir
low
ph
examin
sensit
pseudoviru
infect
lysosomotrop
agent
chloroquin
nh
cl
expect
infect
virus
pseudotyp
vsvg
reduc
chloroquin
nh
cl
dosedepend
manner
respect
protein
detect
western
blot
antibodi
band
detect
cell
transfect
empti
vector
lane
acrylamid
gradient
gel
use
fig
c
respect
contrast
sar
pseudoviru
infect
virtual
unaffect
suggest
sarscov
infect
proce
acid
phindepend
manner
assess
whether
sar
pseudovirus
gener
could
use
quantifi
virusneutr
antibodi
examin
suscept
convalesc
sera
sarscovinfect
patient
shown
fig
sera
two
patient
abl
specif
neutral
sar
pseudovirus
convalesc
sera
could
neutral
vsvg
pseudovirus
neutral
activ
observ
normal
serum
determin
neutral
antibodi
titer
virusinfect
patient
perform
assay
serial
dilut
sera
seven
patient
shown
fig
antibodi
level
quit
similar
patient
neutral
titer
although
pseudoviru
neutral
assay
sensit
quantit
safe
one
disadvantag
count
individu
xgalstain
cell
microscop
overcom
problem
look
possibl
autom
data
collect
procedur
use
elispot
reader
immunospot
analyz
cellular
technolog
ltd
although
instrument
commonli
use
quantifi
antigenspecif
cell
cytokin
respons
count
chromogen
immunospot
eg
ifng
ration
might
abl
detect
xgalstain
blue
cell
shown
fig
problem
use
instrument
count
spot
singlecel
resolut
analysi
highli
effici
entir
plate
could
process
less
min
virusinfect
cell
appear
doublet
pose
problem
paramet
analysi
softwar
could
adjust
count
two
stain
cell
adjac
one
number
infecti
foci
count
quit
linear
function
viru
inoculum
fig
valid
methodolog
procedur
could
use
quantifi
assay
base
xgal
stain
cell
eg
recombin
vaccinia
virus
express
hgalactosidas
studi
express
sarscov
sglycoprotein
abl
pseudotyp
mulv
particl
sar
pseudovirus
abl
effici
infect
vero
cell
shown
support
sarscov
infect
infect
requir
low
ph
suggest
viral
entri
mediat
direct
fusion
event
viral
plasma
membran
result
consist
previou
report
celltocel
fusion
mediat
sprotein
cellular
receptor
occur
neutral
ph
xiao
et
al
howev
result
direct
disagr
recent
publish
articl
simmon
et
al
three
major
differ
experiment
procedur
two
studi
first
pseudotyp
mulv
particl
wherea
simmon
et
al
use
second
use
authent
sglycoprotein
wherea
use
ctermin
fusion
protein
includ
epitop
polyhistidin
tag
total
estim
extra
amino
acid
whether
discrep
result
due
use
differ
sglycoprotein
andor
differ
viru
core
need
investig
third
differ
studi
concentr
lysosomotrop
agent
use
use
nh
cl
amount
suffici
inhibit
vsvgmediat
fusion
fig
picardmaureau
et
al
use
millimolar
mm
amount
concentr
nh
cl
could
secondari
effect
sglycoprotein
unabl
find
concentr
chloroquin
use
studi
interest
note
simmon
et
al
observ
pseudoviru
infect
requir
low
ph
sproteinmedi
celltocel
fusion
sar
pseudovirus
gener
could
specif
inhibit
convalesc
sera
sarscov
infect
patient
indic
sglycoprotein
sarscov
target
neutral
antibodi
coronavirus
major
purpos
gener
sar
pseudovirus
devis
assay
system
assess
virusneutr
antibodi
safe
rapidli
without
use
infecti
replicationcompet
sarscov
result
studi
indic
sar
pseudovirus
could
use
evalu
efficaci
variou
sglycoproteinbas
vaccin
candid
elicit
virusneutr
antibodi
could
also
use
perform
structurefunct
analys
sglycoprotein
due
larg
size
sarscov
genom
would
difficult
perform
analys
directli
context
viru
mention
potenti
safeti
hazard
work
contrast
mutat
analys
protein
could
perform
readili
use
pseudovirus
attempt
character
biochem
immunolog
properti
sprotein
hamper
fact
antibodi
titer
protein
convalesc
sera
extrem
low
abl
identifi
faint
band
western
blot
high
background
attempt
detect
protein
immunofluoresc
radioimmunoprecipit
assay
less
success
contrast
convalesc
sera
success
use
detect
sarscovinfect
cell
immunofluoresc
assay
hsueh
et
al
peiri
et
al
togeth
avail
data
seem
suggest
sprotein
might
immunogen
least
compar
viral
protein
fact
immunoreact
analys
panel
synthet
peptid
deriv
membran
nucleocapsid
n
protein
suggest
n
protein
might
immunogen
protein
nonimmunogen
natur
sprotein
might
present
potenti
problem
develop
vaccin
elicit
potent
neutral
antibodi
sarscov
regard
interest
note
sprotein
highli
glycosyl
potenti
asparaginelink
glycosyl
site
base
analys
ectodomain
protein
carbohydr
residu
account
approxim
kda
base
mobil
sdspage
glycan
primarili
high
mannos
andor
hybrid
type
howev
need
verifi
use
protein
produc
nonvaccinia
viru
express
system
viru
infect
could
possibl
affect
cellular
glycosyl
machineri
extens
glycosyl
envelop
glycoprotein
one
major
obstacl
elicit
good
humor
respons
protein
develop
effect
vaccin
viru
cho
remain
seen
whether
extent
glycan
sprotein
affect
immunogen
properti
protein
interestingli
potenti
glycosyl
site
cluster
three
region
protein
fig
ntermin
middl
ctermin
shown
individu
glycosyl
site
surfac
glycoprotein
may
differ
function
import
evad
immun
respons
other
critic
maintain
proper
protein
structur
necessari
interact
cellular
receptor
mediat
membran
fusion
ogert
et
al
reitter
et
al
addit
studi
need
determin
whether
glycosyl
site
differ
cluster
sprotein
serv
differ
function
absenc
effect
vaccin
andor
antivir
drug
sarscov
earli
detect
virusinfect
patient
would
critic
effect
contain
futur
epidem
quantit
rtpcrbase
diagnost
assay
describ
sarscov
grant
et
al
lau
et
al
ng
et
al
poon
et
al
poon
et
al
tang
et
al
yam
et
al
despit
high
sensit
util
limit
detect
rate
vari
wide
depend
clinic
sampl
protocol
use
assay
ii
window
detect
limit
earli
stage
infect
iii
assay
suitabl
routin
surveil
antibodi
sar
protein
shown
appear
earli
day
onset
ill
hsueh
et
al
therefor
develop
highthroughput
serologybas
diagnost
could
complement
pcrbase
assay
regard
virusneutr
assay
could
use
confirmatori
test
would
enhanc
accuraci
earli
diagnosi
sarscov
neutral
antibodi
import
viru
clearanc
assay
could
also
use
assess
diseas
prognosi
either
case
avail
sar
pseudovirus
allow
avoid
use
infecti
sarscov
overal
clone
strategi
shown
fig
two
parent
plasmid
encod
sarscov
gene
urbani
strain
pentr
pcr
obtain
us
center
diseas
control
prevent
two
sproteinexpress
plasmid
pcdna
pcdna
gener
use
invitrogen
gene
pcdna
transfer
pentr
bamhi
ecori
fragment
lack
origin
translat
stop
codon
taa
chang
aat
ecori
restrict
site
gaattc
pcdna
stop
codon
construct
replac
swaiecori
fragment
pcdna
fragment
pcr
gener
phcmv
bamhi
ecori
fragment
pcdna
insert
bamhi
site
phcmvg
follow
blunt
end
klenow
construct
ptm
bamhi
xhoi
fragment
pcdna
clone
correspond
site
ptmndei
cho
et
al
despit
fact
ptm
small
openread
frame
encod
eight
amino
acid
intern
ribosom
entri
site
ptmndei
vector
gene
sprotein
effici
express
plasmid
use
without
modif
gener
ptmeshi
end
ectodomain
pcr
amplifi
use
sens
primer
gtc
aac
att
caa
aaa
nt
gene
antisens
primer
gaa
gcg
gat
cccggg
tta
gtg
atg
gtg
gtg
atg
atg
ttg
ctc
ata
ttt
tcc
basepair
region
nt
shown
bold
six
histidin
residu
italic
amplifi
fragment
digest
swai
nt
smai
underlin
subsequ
clone
ptm
digest
swai
stui
cell
cultur
protein
express
western
blot
cell
line
except
vero
maintain
dmem
supplement
fetal
bovin
serum
fb
mm
lglutamin
penicillin
streptomycin
antibiot
vero
cell
maintain
emem
supplement
plu
mm
nonessenti
amino
acid
cell
cultur
jc
co
incub
express
sprotein
cell
transfect
plasmid
calcium
phosphat
precipit
method
briefli
ml
cacl
solut
contain
ag
plasmid
slowli
mix
hb
mm
hepe
mm
na
hpo
mm
nacl
ph
mixtur
ad
cell
overnight
incub
cultur
medium
replac
cell
incub
two
addit
day
express
ptm
ptmeshi
transfect
cell
infect
fuerst
et
al
multipl
infect
follow
day
infect
cell
lyse
hypoton
cell
lysi
buffer
mm
tri
ph
mm
nacl
mm
mgcl
insolubl
cell
debri
nuclei
remov
brief
centrifug
microfug
cell
lysat
subject
sdspage
western
blot
sprotein
detect
either
pool
convalesc
sera
dilut
antihi
ctermin
monoclon
antibodi
invitrogen
dilut
follow
horseradish
peroxidaseconjug
goat
antihuman
antimous
igg
antibodi
pierc
respect
protein
band
visual
use
supersign
west
pico
chemiluminesc
detect
system
pierc
molecular
weight
protein
band
approxim
mobil
standard
molecular
weight
marker
pseudovirus
gener
previous
describ
kim
et
al
briefli
mulv
packag
cell
line
schnierl
et
al
transfect
pcdna
phcmv
phcmvg
burn
et
al
kim
et
al
use
either
calcium
phosphat
precipit
lipofect
lipofectin
invitrogen
method
two
day
posttransfect
day
sar
pseudoviru
cell
cultur
medium
harvest
subject
centrifug
g
min
remov
cell
debri
supernat
aliquot
store
jc
use
viru
stock
viru
titer
determin
vero
cell
sarss
vsvg
chengmay
et
al
deng
et
al
pseudotyp
virus
typic
cell
infect
infecti
unit
h
cell
wash
pb
incub
fix
formaldehyd
glutaraldehyd
pb
min
room
temperatur
cell
wash
twice
pb
incub
freshli
prepar
stain
solut
pb
contain
mm
potassium
ferricyanid
mm
potassium
ferrocyanid
mm
magnesium
chlorid
mgml
xgal
h
jc
routin
analys
xgalstain
blue
cell
manual
count
use
invert
microscop
determin
phdepend
viral
entri
vero
cell
incub
cultur
medium
contain
chloroquin
h
jc
ad
virus
vsvg
sarss
pseudovirus
allow
adsorb
cell
h
jc
absenc
chloroquin
follow
adsorpt
viru
inoculum
remov
cell
wash
infect
allow
proceed
h
absenc
chloroquin
nh
cl
cell
incub
due
minim
cytotox
nh
cl
present
throughout
infect
period
includ
h
incub
viru
addit
infect
done
duplic
neutral
assay
perform
previous
describ
kim
et
al
use
convalesc
sera
day
postonset
symptom
obtain
cdc
patient
hospit
queen
mari
hospit
hong
kong
approxim
infecti
unit
pseudovirus
incub
serial
dilut
heatinactiv
jc
min
convalesc
normal
sera
h
jc
mixtur
subsequ
ad
vero
sarss
vsvg
cell
viru
infect
allow
proceed
anoth
h
virusneutr
activ
determin
rel
serum
control
gener
pseudoviru
infect
procedur
describ
major
differ
plate
white
membran
bottom
normal
use
elispot
assay
plate
bd
bioscienc
util
rather
regular
tissu
cultur
plate
immunospot
analyz
cellular
technolog
ltd
use
per
manufactur
recommend
